With the US still battling the opioid epidemic, the most widely-used overdose reversal agent – Emergent BioSolutions’ Narcan – can now be bought over the counter at pharma
Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis' mavoglurant, in clinical trials for cocaine use disorder (CU
Addiction treatment specialist Spero Health has expanded an agreement to use Pear Therapeutics’ prescription digital therapeutics (DTx) in its network of US clinics.
Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds for the digital hea
Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.